Skip to main content
. Author manuscript; available in PMC: 2016 Jul 16.
Published in final edited form as: Med Oncol. 2010 Sep 28;28(Suppl 1):S39–S47. doi: 10.1007/s12032-010-9682-1

Table 3.

Type of DFS Event for Eligible Patients

Tam+Fenretinide Tam+Placebo Combined
Type (n=206) (n=213) (n=419)

New Primary Breast Cancer 7 2 9
Recurrence, Local-Regional Only 11 7 18
Recurrence, Distant Involvement 18 21 39
Recurrence, Sites Unknown 2 0 2
Death Without Recurrence 13 14 27

Total 51 44 95